CStone entered into an exclusive agreement to license in the Numab’s tri-specific antibody-based molecule ND021 in Greater China, Singapore and Korea
This deal allows CStone to enter the 4-1BB race with a bi-/tri-specific 4-1BB/PD-L1 drug candidate, with favourable risk/reward, in our view
Maintain BUY rating and TP at HK$19.83